LELucie Ecker

Lucie Ecker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucie Ecker has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Post-MIS-C cardiovascular outcomes: a systematic review

    by Giancarlo Alvarado-Gamarra, Katherine Alcala-Marcos, Carlos R. Celis, Pía Balmaceda-Nieto, Luigi Cieza, Cristian Morán-Mariños, Pamela Grados-Espinoza, Carlos Alva-Díaz, Lucie Ecker, Theresa J. Ochoa, et al.

    Limited knowledge and variability in findings exist regarding the resolution of cardiovascular outcomes following Multisystem Inflammatory Syndrome in Children (MIS-C). We conducted a systematic review to estimate the frequency of cardiovascular outcomes following MIS-C. A systematic search was conducted in Pubmed/Medline, Scopus, Embase, SciELO, LILACS, Cochrane Library, Web of Science, and medRxiv were searched up to February 2024. We included studies reporting cardiovascular events that began in acute MIS-C and persisted after discharge. Screening and data extraction were performed by independent reviewers. We performed a random-effects meta-analysis and assessed the certainty of the evidence using the GRADE approach. Eighty-four studies (n = 4,778) were included; seven had a comparator group. The frequency of cardiovascular outcomes—including coronary abnormalities (Z-score ≥ 2), left ventricle ejection fraction < 55%, diastolic dysfunction, myocarditis, and pericardial effusion—decreased over time, with most resolving by 6 to 9 months. However, cardiac magnetic resonance imaging studies identified myocardial edema and/or fibrosis persisting up to 12 months, and two studies reported coronary abnormalities at 18- to 24-month follow-up. Evidence certainty was very low. Compared to children with COVID-19 or healthy controls, MIS-C showed more cardiovascular events and greater subclinical myocardial dysfunction, as assessed by strain analysis, during a 6-month follow-up. Compared with other etiologies of myocarditis, MIS-C myocarditis was associated with better cardiovascular outcomes but shorter exercise duration and lower aerobic capacity on stress testing. Conclusions: Cardiovascular outcomes following MIS-C improved over time, but certain subclinical cardiac abnormalities persisted up to 12 to 24 months. These findings may support long-term follow-up after MIS-C. Trial registration: Protocol registration number: PROSPERO, CRD42022336784. What is Known: • Multisystem Inflammatory Syndrome in Children (MIS-C) may lead to persistent cardiovascular complications. However, studies show variability in their findings, with heterogeneous follow-up durations—including limited long-term data—small sample sizes, and data mostly originating from single-center experiences in high-income countries. What is New: • Cardiovascular outcomes following MIS-C improved over time across global reports, most resolving by 6–9 months; however, advanced non-invasive methods have identified subclinical cardiac abnormalities up to 12–24 months. This may support the development of evidence-based follow-up recommendations after MIS-C.


  • Open Access

    Pandemic Social Distancing and Declines in Nasopharyngeal Carriage of Pneumococcus and Related Antimicrobial-Resistant Genes: Evidence From Household-Based Cohort Studies in Lima, Peru

    by Cara E Charnogursky, Ana I Gil, Lucie Ecker, Rubelio Cornejo, Stefano Rios, Mayra Ochoa, Bia Peña, Omar Flores, Angela Jones, Karen Beeri, et al.

    Background: Peru implemented restrictive social distancing policies during the COVID-19 pandemic. Few studies have examined patterns of nasopharyngeal pneumococcal carriage and related antimicrobial-resistant genes (ARGs), particularly in community-based settings with intense social distancing policies. Methods: Nasopharyngeal swabs were systematically obtained weekly from children and adults enrolled in 2 household-based prospective cohorts in Lima, Peru: prepandemic (2019–2020) and pandemic (2020–2021). Selected samples underwent sequencing-based detection of Streptococcus pneumoniae and related ARGs. We compared detections of pneumococcus and erm genes between cohorts during the same 7 epidemiologic weeks in 2020 and 2021 while accounting for relevant covariates and household clustering by mixed effects logistic regression models. Results: An overall 663 specimens from 114 individuals were included: 407 and 256 samples from the prepandemic and pandemic cohorts, respectively. Carriage of pneumococcus was lower in the pandemic cohort (3.5%) as compared with the prepandemic cohort (23.6%; adjusted odds ratio, 0.09; 95% CI, .02–.32). Similarly, erm gene carriage was lower in the pandemic cohort (28.1%) as compared with the prepandemic cohort (58.7%; adjusted odds ratio, 0.21; 95% CI, .10–.46). Conclusions: We observed a substantial reduction in the carriage of S pneumoniae and related ARGs in community-dwelling individuals during a pandemic period with intense social distancing in Lima, Peru.


  • Open Access

    Epidemiology of norovirus disease in the first 2 years of life: A prospective multisite cohort study in Lima, Peru

    by Claudio F. Lanata, Giselle Soto, Ana I. Gil, Joan Neyra, Rubelio Cornejo, Candice Romero, Lucie Ecker, Maria L. Huaylinos, Sayda La Rosa, Ana Goios, et al.


  • Open Access

    Pooling of six respiratory samples for the detection of SARS-CoV-2: A validation and cost study in a cohort in Lima, Peru

    by Mayra Ochoa, Bia Peña, Omar Flores, Ana I. Gil, Lucie Ecker, Rubelio Cornejo, Leigh M. Howard, Carlos G. Grijalva, Claudio F. Lanata

  • Open Access

    SARS‐CoV‐2 infections in households in a peri‐urban community of Lima, Peru: A prospective cohort study

    by Claudio F. Lanata, Ana I. Gil, Lucie Ecker, Rubelio Cornejo, Stefano Rios, Mayra Ochoa, Bia Peña, Omar Flores, Leigh M. Howard, Carlos G. Grijalva

    Background: We assessed the prevalence and incidence of SARS‐CoV‐2 infections in a prospective study of households in Lima, Peru.Methods: Households with a child, a young adult 18–50 years, and an adult age >50 years in peri‐urban Lima were followed with twice‐a‐week household visits during a 2‐month period. Nasal swabs and saliva specimens were collected twice weekly, and nasopharyngeal swabs were collected weekly from each participant, regardless of symptoms. Laboratory‐confirmed SARS‐CoV‐2 infection was defined by two RT‐PCR tests from any of the collected specimens within a week. Blood samples collected at enrollment and end of follow‐up were tested with rapid serological tests. We calculated the prevalence and incidence of laboratory‐confirmed SARS‐CoV‐2 infections.Results: We enrolled 132 participants from 44 households: 44 children, 44 young adults, and 44 older adults. A total of 13 SARS‐CoV‐2 infections were detected in eight households, for an overall period prevalence of 9.85% (95% confidence interval [CI]: 5.35–16.25). Most (61.54%) infections were symptomatic. Eight of 11 (72.73%) SARS‐CoV‐2 detections corresponded to the Lambda variant. During 218.79 person‐months at risk of follow‐up, there were six new SARS‐CoV‐2 infections detected (2.74 per 100 person‐month, 95% CI: 1.25–6.04). At enrollment, 59 of 128 participants tested had positive SARS‐CoV‐2 IgG serology (46.09%, 95% CI: 37.25–55.12). Five of six new infections occurred among participants with negative baseline serology.Conclusions: We demonstrated high incidence of SARS‐CoV‐2 infections in households, especially among subjects without evidence of prior infection, most of them not detected by the Ministry of Health system.


  • Open Access

    Desarrollo de las Vacunas contra el SARS-CoV-2 y las implicancias relacionadas a la aparición de las variantes del virus

    by Claudio F. Lanata-De Las Casas, Lucie Ecker-Ledesma, Rubelio E. Cornejo-Cotos, Carlos R. Celis-Albújar, Carmen del Pilar Díaz-Parra, Sheby A. Ricalde-Ponce de León, Omar Flores-Salmón, Mayra Ochoa Porras, Bia Peña-Peralta, Ana I. Gil-Merino

    La aparición de la pandemia causada por el virus SARS-CoV-2 tomó desprevenido al mundo entero. Sin embargo, la reacción ha sido asombrosa. En poco más de un año de la aparición del virus, se cuenta con cientos de vacunas en desarrollo y varias de ellas vienen siendo aplicadas en casi todo el mundo. En este manuscrito revisamos el estado actual del desarrollo de las vacunas, resaltando aquéllas que cuentan con estudios de Fase III (eficacia) o IV (efectividad). Además, revisamos las variantes de interés y de preocupación del virus SARS-CoV-2 detectadas hasta el momento y qué se sabe sobre de la eficacia de las vacunas contra ellas.